BACKGROUND: Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) predict acute cellular rejection after liver transplantation (LTx) or intestine transplantation (ITx) in small cohorts of children and can enhance immunosuppression management, but await validation and clinical implementation. METHODS: To establish safety and probable benefit, CD154+TcM were measured in cryopreserved samples from 214 children younger than 21 years (National Clinical Trial 1163578). Training set samples (n = 158) were tested with research-grade reagents and 122 independent validation set samples were tested with current good manufacturing practices-manufactured reagents after assay standardization and reproducibility testing. Recipient CD154+TcM induced by stimulation with donor cells were expressed as a fraction of those induced by HLA nonidentical cells in parallel cultures. The resulting immunoreactivity index (IR) if greater than 1 implies increased rejection-risk. RESULTS: Training and validation set subjects were demographically similar. Mean coefficient of test variation was less than 10% under several conditions. Logistic regression incorporating several confounding variables identified separate pretransplant and posttransplant IR thresholds for prediction of rejection in the respective training set samples. An IR of 1.1 or greater in posttransplant training samples and IR of 1.23 or greater in pretransplant training samples predicted LTx or ITx rejection in corresponding validation set samples in the 60-day postsampling period with sensitivity, specificity, positive, and negative predictive values of 84%, 80%, 64%, and 92%, respectively (area under the receiver operator characteristic curve, 0.792), and 57%, 89%, 78%, and 74%, respectively (area under the receiver operator characteristic curve, 0.848). No adverse events were encountered due to phlebotomy. CONCLUSIONS: Allospecific CD154+T-cytotoxic memory cells predict acute cellular rejection after LTx or ITx in children. Adjunctive use can enhance clinical outcomes.
BACKGROUND: Allospecific CD154+T-cytotoxic memory cells (CD154+TcM) predict acute cellular rejection after liver transplantation (LTx) or intestine transplantation (ITx) in small cohorts of children and can enhance immunosuppression management, but await validation and clinical implementation. METHODS: To establish safety and probable benefit, CD154+TcM were measured in cryopreserved samples from 214 children younger than 21 years (National Clinical Trial 1163578). Training set samples (n = 158) were tested with research-grade reagents and 122 independent validation set samples were tested with current good manufacturing practices-manufactured reagents after assay standardization and reproducibility testing. Recipient CD154+TcM induced by stimulation with donor cells were expressed as a fraction of those induced by HLA nonidentical cells in parallel cultures. The resulting immunoreactivity index (IR) if greater than 1 implies increased rejection-risk. RESULTS: Training and validation set subjects were demographically similar. Mean coefficient of test variation was less than 10% under several conditions. Logistic regression incorporating several confounding variables identified separate pretransplant and posttransplant IR thresholds for prediction of rejection in the respective training set samples. An IR of 1.1 or greater in posttransplant training samples and IR of 1.23 or greater in pretransplant training samples predicted LTx or ITx rejection in corresponding validation set samples in the 60-day postsampling period with sensitivity, specificity, positive, and negative predictive values of 84%, 80%, 64%, and 92%, respectively (area under the receiver operator characteristic curve, 0.792), and 57%, 89%, 78%, and 74%, respectively (area under the receiver operator characteristic curve, 0.848). No adverse events were encountered due to phlebotomy. CONCLUSIONS: Allospecific CD154+T-cytotoxic memory cells predict acute cellular rejection after LTx or ITx in children. Adjunctive use can enhance clinical outcomes.
Authors: Joshua J Augustine; David S Siu; Michael J Clemente; James A Schulak; Peter S Heeger; Donald E Hricik Journal: Am J Transplant Date: 2005-08 Impact factor: 8.086
Authors: C Ashokkumar; A Talukdar; Q Sun; B W Higgs; J Janosky; P Wilson; G Mazariegos; R Jaffe; A Demetris; J Dobberstein; K Soltys; G Bond; A W Thomson; A Zeevi; R Sindhi Journal: Am J Transplant Date: 2008-10-31 Impact factor: 8.086
Authors: Alexander Kroemer; Khalid Khan; Stuart S Kaufman; Jiman Kang; Joshua Weiner; Anju Duttargi; Leonid Belyayev; Chethan Ashokkumar; Rakesh Sindhi; Olga A Timofeeva; Michael Zasloff; Cal S Matsumoto; Thomas M Fishbein Journal: Am J Transplant Date: 2020-08-30 Impact factor: 8.086
Authors: Nadja Stobutzki; Stephan Schlickeiser; Mathias Streitz; Katarina Stanko; Kim-Long Truong; Levent Akyuez; Katrin Vogt; Christine Appelt; Andreas Pascher; Olga Blau; Undine A Gerlach; Birgit Sawitzki Journal: Front Immunol Date: 2019-05-07 Impact factor: 7.561
Authors: Mylarappa Ningappa; Syed A Rahman; Brandon W Higgs; Chethan S Ashokkumar; Nidhi Sahni; Rakesh Sindhi; Jishnu Das Journal: Cell Rep Med Date: 2022-04-19
Authors: Alberto Sánchez-Fueyo; Gavin Whitehouse; Nathali Grageda; Matthew E Cramp; Tiong Y Lim; Marco Romano; Sarah Thirkell; Katie Lowe; Laura Fry; Julie Heward; Alex Kerr; Jakia Ali; Chris Fisher; Gillian Lewis; Andrew Hope; Elisavet Kodela; Mike Lyne; Farzin Farzaneh; Shahram Kordasti; Irene Rebollo-Mesa; Juan Jose Lozano; Niloufar Safinia; Nigel Heaton; Robert Lechler; Marc Martínez-Llordella; Giovanna Lombardi Journal: Am J Transplant Date: 2020-02-03 Impact factor: 8.086